Currently, there are 51.65M common shares owned by the public and among those 43.07M shares have been available to trade.
The company’s stock has a 5-day price change of -16.97% and -7.79% over the past three months. BDTX shares are trading 60.14% year to date (YTD), with the 12-month market performance up to 32.35% higher. It has a 12-month low price of $1.62 and touched a high of $7.66 over the same period. BDTX has an average intraday trading volume of 652.72K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -21.50%, -20.84%, and -5.84% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Black Diamond Therapeutics Inc (NASDAQ: BDTX) shares accounts for 72.13% of the company’s 51.65M shares outstanding.
It has a market capitalization of $254.25M and a beta (3y monthly) value of 2.49. The earnings-per-share (ttm) stands at -$1.54. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.84% over the week and 9.31% over the month.
Analysts forecast that Black Diamond Therapeutics Inc (BDTX) will achieve an EPS of -0.35 for the current quarter, -0.35 for the next quarter and -1.54 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.41 while analysts give the company a high EPS estimate of -0.41. Comparatively, EPS for the current quarter was -0.45 a year ago. Earnings per share for the fiscal year are expected to increase by 25.58%, and -8.01% over the next financial year.
Looking at the support for the BDTX, a number of firms have released research notes about the stock. Raymond James stated their Outperform rating for the stock in a research note on July 31, 2024, with the firm’s price target at $20. Stifel was of a view on June 30, 2023 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on June 28, 2023, issuing a price target of $11. Wedbush on their part issued Outperform rating on June 27, 2023.
